Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The Mesenteric Masquerader: A Rare Primary Neuroendocrine Tumor of the Mesentery.

Created on 23 Aug 2026

Authors

Manogya Khanna, Subhash Chawla, Harsh Gupta, Mrugen Thakor, Vishesh Dhawan

Published in

Cureus. Volume 18. Issue 7. Pages e113235. Epub Jul 23, 2026.

Abstract

Primary neuroendocrine tumors (NETs) arising exclusively within the mesentery, without an identifiable gastrointestinal or pancreatic primary, are exceedingly rare and often present with non-specific symptoms, making preoperative diagnosis challenging. We report the case of an 80-year-old female who presented with a six-month history of right-sided abdominal pain and a palpable abdominal mass. Contrast-enhanced computed tomography of the abdomen revealed a well-defined soft tissue lesion measuring 7.1 × 4.4 × 5.3 cm in the right iliac fossa mesentery, with vascular supply from the superior mesenteric artery. The mass was successfully excised laparoscopically en masse. Histopathological examination demonstrated a WHO Grade I well-differentiated NET with lymphovascular invasion and negative resection margins. Immunohistochemistry showed positivity for pan-cytokeratin, synaptophysin, chromogranin, INSM1, and CD56. This case highlights the diagnostic challenge of primary mesenteric NETs and supports surgical resection as the definitive management. Careful postoperative surveillance is warranted due to the potential for recurrence.

PMID:
42633364
Bibliographic data and abstract were imported from PubMed on 23 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement